Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening

Policy # 00003
Original Effective Date: 08/25/2003
Current Effective Date: 11/13/2019

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider analysis of stool samples using the Cologuard® multi-targeted stool deoxyribonucleic acid (DNA) test as a screening technique for colorectal cancer (CRC) at intervals of one test every three years to be eligible for coverage.**

Patient Selection Criteria
Cologuard multi-targeted stool deoxyribonucleic acid (DNA) test as a screening technique for colorectal cancer (CRC) will be eligible for coverage in patients meeting all of the following criteria:

- Age 50 to 85 years, AND
- Asymptomatic (no signs or symptoms of colorectal disease including but not limited to lower gastrointestinal pain, blood in stool, positive guaiac fecal occult blood test or fecal immunochemical test), AND
- At average risk of developing colorectal cancer ([CRC] no personal history of adenomatous polyps, colorectal cancer [CRC], or inflammatory bowel disease, including Crohn’s disease and ulcerative colitis; no family history of colorectal cancers [CRCs], familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer [HNPCC]).
Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening

Policy # 00003
Original Effective Date: 08/25/2003
Current Effective Date: 11/13/2019

**When Services Are Considered Investigational**
*Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.*

Based on review of available data, the Company considers deoxyribonucleic acid (DNA) analysis of stool samples as a screening technique for colorectal cancer (CRC) when patient selection criteria are not met or using any stool deoxyribonucleic acid (DNA) test other than Cologuard to be investigational.*

**Background/Overview**
Detection of genetic abnormalities associated with CRC in stool samples has been proposed as a screening test for CRC. This technology is another potential alternative to currently available screening approaches such as fecal occult blood testing, fecal immunochemical testing (FIT), or colonoscopy.

Several cellular genetic alterations have been associated with CRC. In the proposed multistep model of carcinogenesis, the tumor suppressor gene p53 and the proto-oncogene KRAS are most frequently altered. Mutations in APC (adenomatous polyposis coli) genes and epigenetic markers (e.g., hypermethylation of specific genes) have also been detected. CRC is also associated with DNA replication errors in microsatellite sequences (termed microsatellite instability or MSI) in patients with Lynch syndrome (formerly known as [HNPCC]) and in a subgroup of patients with sporadic colon carcinoma. Tumor-associated gene mutations and epigenetic markers can be detected in exfoliated intestinal cells in stool specimens. Since cancer cells are shed into stool, tests have been developed that detect these genetic alterations in the DNA from shed CRC cells isolated from stool samples.

**FDA or Other Governmental Regulatory Approval**

**U.S. Food and Drug Administration (FDA)**
On August 12, 2014, Cologuard™‡ (Exact Sciences) was approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process as an automated fecal DNA testing product (P130017). Cologuard is intended for the qualitative detection of colorectal neoplasia associated DNA markers and of occult hemoglobin in human stool. A positive result may indicate...
Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening

Policy # 00003
Original Effective Date: 08/25/2003
Current Effective Date: 11/13/2019

the presence of CRC or advanced adenoma and should be followed by diagnostic colonoscopy. Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for CRC. Cologuard is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Over the past several years, different stool DNA tests have been evaluated in studies, and some have been marketed. One previously marketed test, PreGen-Plus™ (LabCorp), tests for 21 different variants in the p53, adenomatous polyposis coli, and KRAS genes; the BAT-26 microsatellite instability marker; and incorporates the DNA Integrity Assay (DIA®). PreGen-Plus has not been cleared by FDA. In January 2006, FDA informed LabCorp that PreGen-Plus may be subject to FDA regulation as a medical device. As a consequence, and as a result of studies showing better performance of other tests, this test is no longer offered. Another previously marketed test is called ColoSure™ (OncoMethylome Sciences; now MDxHealth), which detects aberrant methylation of the vimentin (hV) gene. This test was offered as a laboratory-developed test and is not subject to FDA regulation.

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross and Blue Shield Association technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Supplemental Information
Practice Guidelines and Position Statements
Several recommendations of specialty organizations on stool DNA testing were based largely on the Imperiale et al (2004), which evaluated a different test and should be considered obsolete. This includes 2008 guidelines from the American Cancer Society, 2012 guidelines from the American College of Physicians, and 2009 guidelines from the American College of Gastroenterology.
Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening

Policy #  00003  
Original Effective Date: 08/25/2003  
Current Effective Date: 11/13/2019

National Comprehensive Cancer Network
The National Comprehensive Cancer Network guidelines (v.1.2018) for colorectal cancer (CRC) screening includes use of fecal immunochemical testing-DNA (FIT-DNA) to screen patients with average risk for colon cancer. Following a negative test, the recommendation is to rescreen with any modality after 3 years. Use of FIT-DNA tests is not described for screening of high-risk individuals.

Multi-Society Task Force on Colorectal Cancer
A U.S. Multi-Society task force representing the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy provided recommendations for CRC screening in 2017. The recommended first-tier tests for individuals with average risk were colonoscopy every 10 years, and for individuals who decline colonoscopy, annual FIT. Recommended second-tier tests in patients who declined the first tier tests were computed tomography colonography every 5 years, FIT-DNA every 3 years, or flexible sigmoidoscopy every 5 to 10 years. Capsule colonoscopy was listed as a third tier test. The task force recommended, “[computed tomography] colonography every 5 years or FIT-fecal DNA every 3 years (strong recommendation, low quality evidence, or flexible sigmoidoscopy every 5-10 years (strong recommendation, high quality evidence) in patients who refuse colonoscopy and FIT.”

American Cancer Society
In 2018, the American Cancer Society updated its guidelines for CRC screening for average-risk adults. Regular screening with either a structural examination (ie colonoscopy) or high-sensitivity stool-based test is recommended to start in adults who are 45 years and older (qualified recommendation) or who are 50 years and older (strong recommendation). Recommendations for screening with stool-based tests include FIT repeated every year, high-sensitivity guaiac-based fecal occult blood test repeated every year, or multitarget stool DNA test repeated every 3 years.

U.S. Preventive Services Task Force Recommendations
The U.S. Preventive Services Task Force (USPSTF) published its most recent recommendations for CRC screening in 2016. CRC screening was recommended starting at age 50 years and continuing until age 75 years (A recommendation). The recommendation statement reviewed 7 different screening strategies including FIT-DNA. Regarding comparisons or preferences between the 7 different methods mentioned: “The USPSTF found no head-to-head studies demonstrating that any of the screening strategies it considered are more effective than others, although the tests have varying levels of evidence supporting their effectiveness, as well as different strengths and
Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening

Policy # 00003
Original Effective Date: 08/25/2003
Current Effective Date: 11/13/2019

Limitations…. The screening tests are not presented in any preferred or ranked order….“ USPSTF noted that sensitivity of FIT-DNA is higher that with FIT, but specificity is lower “resulting in more false-positive results, more diagnostic colonoscopies, and more associated adverse events per screening test.”

Medicare National Coverage
In 2014, a Centers for Medicare & Medicaid Services decision memo indicated Medicare Part B will cover the Cologuard test “once every 3 years for beneficiaries who meet all of the following criteria”:

- “Age 50 to 85 years,
- Asymptomatic (no signs or symptoms of colorectal disease including but not limited to lower gastrointestinal pain, blood in stool, positive guaiac fecal occult blood test or fecal immunochemical test), and
- At average risk of developing colorectal cancer (no personal history of adenomatous polyps, colorectal cancer, or inflammatory bowel disease, including Crohn’s Disease and ulcerative colitis; no family history of colorectal cancers or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer).

All other stool DNA tests not otherwise specified above remain nationally non-covered.”

As noted in the Centers for Medicare & Medicaid Services decision memo, the optimal screening interval for Cologuard is unknown. In the interim, Centers for Medicare & Medicaid Services has indicated it will cover Cologuard every 3 years as previously specified and would reevaluate the screening interval after the Food and Drug Administration approval study is completed.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 1.

Table 1. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
</table>

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 5 of 10
Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening

Policy # 00003
Original Effective Date: 08/25/2003
Current Effective Date: 11/13/2019

<table>
<thead>
<tr>
<th>Ongoing</th>
<th>Screening and Risk Factors of Colon Neoplasia</th>
<th>1600</th>
<th>Mar 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01647776</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02419716a</td>
<td>A Longitudinal Study of Cologuard in an Average Risk Population Assessing a Three Year Test Interval</td>
<td>2404</td>
<td>Jul 2020</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

a Denotes industry-sponsored or cosponsored trial.

References

Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening

Policy #  00003
Original Effective Date:  08/25/2003
Current Effective Date:  11/13/2019


Policy History
Original Effective Date:  08/25/2003
Current Effective Date:  11/13/2019
08/19/2003  Medical Policy Committee review
08/25/2003  Managed Care Advisory Council approval
08/03/2005  Medical Director review
08/16/2005  Medical Policy Committee review. No change to coverage eligibility.
08/24/2005  Managed Care Advisory Council approval
07/07/2006  Format revision, including addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility unchanged.
05/02/2007  Medical Director review
05/23/2007  Medical Policy Committee approval. Coverage eligibility unchanged.
05/07/2009  Medical Director review
05/20/2009  Medical Policy Committee approval. Coverage eligibility unchanged.
05/06/2010  Medical Director review
Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening

Policy # 00003
Original Effective Date: 08/25/2003
Current Effective Date: 11/13/2019

06/16/2010 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/01/2011 Coding review
05/05/2011 Medical Director review
05/18/2011 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
05/03/2012 Medical Policy Committee review
05/16/2012 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/04/2013 Coding updated
05/02/2013 Medical Director review
05/22/2013 Medical Policy Implementation Committee approval. No change to coverage.
03/06/2014 Medical Policy Committee review
03/19/2014 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2015 Coding updated
04/02/2015 Medical Policy Committee review
04/20/2015 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
01/01/2016 Coding update: CPT code added
04/07/2016 Medical Policy Committee review
04/20/2016 Medical Policy Implementation Committee approval. Added coverage statement for Cologuard testing every three years in patients meeting criteria.
11/03/2016 Medical Policy Committee review
01/01/2017 Coding update: Removing ICD-9 Diagnosis codes
11/02/2017 Medical Policy Committee review
08/28/2018 Coding update
11/08/2018 Medical Policy Committee review
Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening

Policy # 00003
Original Effective Date: 08/25/2003
Current Effective Date: 11/13/2019

11/07/2019 Medical Policy Committee review

Next Scheduled Review Date: 11/2020

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
   1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
   2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
   3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;

B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.